首页 | 官方网站   微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 824 毫秒
1.
目的系统评价错配修复(MMR)基因缺陷与卵巢癌预后的关系。方法检索从建库至2017年6月15日PubMed、EMBASE、Cochrane、中国学术期刊全文数据库、维普和万方数据库收录的关于错配修复(MMR)基因缺陷与卵巢癌患者预后相关性关系的文献,筛选出符合纳入标准的文献进行循证评价,主要评价指标包括总生存期(OS)和无病生存期(DFS),应用风险比(hazard ratio,HR)和95%CI来评价结局指标,采用RevMan5. 3软件进行Meta分析。结果共纳入8篇文献,3966例患者,研究间异质性较大。其中一篇文献显示MMR基因缺陷与卵巢癌预后有显著相关性(HR=0.41,P=0.007),合并分析显示MMR与卵巢癌患者OS间无统计学意义(3篇研究,HR=0.84,95%CI0.60~1.19,P=0.33)。结论 MMR基因缺陷与卵巢癌预后之间尚未发现显著相关性,可能是由于缺乏足够的相关研究,有待于未来更多高质量的大样本试验进一步研究。  相似文献   

2.
目的通过Meta分析观察二甲双胍对糖尿病合并肺癌患者生存率的影响。方法检索Pub Med、EMbase、CNKI等数据库,筛选并纳入相关文献,提取文献特征,采用STATA 12.0软件计算总的风险比(HR)及95%CI,并评价研究间的异质性、有无发表偏倚。结果共纳入7篇队列研究。总的Meta分析结果显示二甲双胍对肺癌患者的生存率无显著改善作用(HR=0.79,95%CI:0.60~1.04,P=0.098)。根据肺癌病理类型进行的亚组分析结果显示,二甲双胍显著降低小细胞肺癌(SCLC)的全因死亡率(HR=0.52,95%CI:0.29~0.91,P=0.022),而对非小细胞肺癌(NSCLC)(HR=0.78,95%CI:0.46~1.33,P=0.361)和混合型肺癌(HR=0.99,95%CI:0.60~1.64,P=0.977)的全因死亡率无显著影响。根据种族进行的亚组分析显示在亚洲人群中二甲双胍显著降低肺癌的全因死亡率(HR=0.47,95%CI:0.33~0.67,P=0.000,I2=0.00%),而在非亚洲人群未观察到两者存在显著相关(HR=0.97,95%CI:0.73~1.31,P=0.83,I2=80.2%)。发表偏倚检验结果未显示存在发表偏倚证据(Begg:P=0.764;Egger:P=0.854)。结论本项Meta分析显示二甲双胍可显著改善SCLC患者的预后,而对NSCLC的预后无显著改善作用。  相似文献   

3.
目的评估Survivin蛋白和宫颈癌发病风险的相关性。方法利用关键词"Survivin、存活蛋白、子宫颈癌",英文检索词包括"uterine cervical neoplasms、cervical cancer、Survivin",通过Pubmed、Embase、CNKI(China National Knowledge Infrastructure)进行文献检索。检索时限至2015年9月15日。结果最终纳入16篇文献,1 071例患者,其中宫颈癌780例、正常对照291例。宫颈癌和正常对照Survivin蛋白表达差异有统计学意义,RR=0.21、95%CI 0.10~0.46,P=0.000。亚组分析,免疫组化组(IHC组)P=0.001,原位杂交组(ISH组)P=0.038,差异有统计学意义,RT-PCR+IHC组P=0.300,差异无统计学意义。Survivin蛋白定位亚组,Nucleus/Cyto组I~2=75.7%、Cyto组I~2=74.8%、未报道蛋白组I~2=67.8%,异质性较大,应解释异质源。排除异质性大的三项研究后,RR=0.15,95%CI 0.01~1.57,P值未变,分析结果稳定。结论 Survivin蛋白的表达与宫颈癌有显著相关性,在宫颈癌发病过程中起到了促进作用,Survivin基因可以作为宫颈癌治疗靶点。  相似文献   

4.
目的对BRCA突变与乳腺癌患者生存之间的关系进行meta分析,探讨BRCA突变对乳腺癌预后的影响。方法计算机检索PubMed数据库、Cochrane临床试验数据库、荷兰医学文摘EMBase数据库有关文献,检索时限从建库开始至2018年12月,由2名研究者按照纳入标准进行文献筛选、提取和质量评估,提取主要预后指标为总生存率(OS),次要预后指标包括乳腺癌特异性生存率(BCSS)和无事件生存率(EFS),采用Stata12.0软件进行数据分析及合成,对风险比(HR)和95%置信区间(CI)进行汇总,合并效应量行meta分析。结果最终纳入34篇文献,共计35 025例乳腺癌患者,其中BRCA1基因突变患者为1 508例,BRCA2基因突变患者为739例,BRCA1突变携带者OS低于非携带者,差异有统计学意义(HR=1.63,95%CI:1.33~2.00,P=0.000),BRCA1突变携带者与BCSS、EFS无相关性,差异无统计学意义(HR=1.14,95%CI:0.81~1.61,P=0.448;HR=1.18,95%CI:0.94~1.46,P=0.149)。BRCA2突变携带者OS低于非携带者,差异有统计学意义(HR=1.47,95%CI:1.06~2.02,P=0.020),BRCA2突变携带者与BCSS、EFS无相关性,差异无统计学意义(HR=1.21,95%CI:0.84~1.73,P=0.302;HR=1.09,95%CI:0.81~1.47,P=0.558)。结论BRCA1和BRCA2基因突变与乳腺癌患者的OS相关,但对其BCSS和EFS无显著影响,在亚组分析中BRCA1和BRCA2基因突变的乳腺癌患者经内分泌治疗后生存率有所改善,结果可能对BRCA突变携带者的治疗和预后具有重要意义。  相似文献   

5.
目的:采用Meta分析方法系统性评价COX-2过表达与浆液性卵巢癌预后的相关性。方法:采用计算机检索中国知网(CNKI)、维普(VIP)、万方(WanFang Data)和PubMed等数据库及会议论文,搜集COX-2的表达与浆液性卵巢癌预后的队列研究,检索时限从建库至2018年11月1日。由2位研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用R3.5.1软件进行分析。结果:共纳入7项研究。Meta分析结果显示:COX-2过表达的患者在总生存期(overall survival,OS;HR=1.57,95%CI:1.26~1.95)、无病生存期(disease-free survival,DFS;HR=2.19,95%CI:1.30~3.68)等方面均差于COX-2低表达的患者。结论:COX-2过表达可能是浆液性卵巢癌患者预后不良的指标。  相似文献   

6.
目的系统评价外周血雄激素受体剪接变异体7(AR-V7)检测在预测去势抵抗性前列腺癌患者预后中的作用。方法计算机检索PubMed、EMBASE、Cochrane library、中国期刊全文数据库(CNKI),检索时间均从建库至2018年5月,纳入探究外周血AR-V7检测与激素抵抗性前列腺癌预后关系的临床研究。根据纽卡斯尔-渥太华(NOS)量表对纳入文献进行质量评价,采用RevMan5.3软件进行Meta分析,研究结局为无进展生存期(PFS)和总生存期(OS)。结果最终纳入英文文献6篇,共计483例患者。固定效应模型显示:AR-V7阳性患者较AR-V7阴性患者预后差。临床或影像PFS:[HR=3.28,95%CI (2.38,4.51),P0.000 1],OS:[HR=2.68,95%CI (1.89,3.80),P0.000 1]。根据治疗药物不同对OS进行亚组分析,结果显示:紫杉醇类化疗药物[HR=1.35,95%CI (0.56,3.25),P=0.50],激素类药物:[HR=3.05,95%CI(2.09,4.47),P0.000 1],提示对于ARV7阳性患者,紫杉醇类化疗药物较激素类药物可降低风险比。结论外周血AR-V7阳性前列腺癌患者与AR-V7阴性者相比预后较差,血中检测AR-V7可作为前列腺癌患者预后预测指标,并可对前列腺癌的治疗方案选择提供指导意义。  相似文献   

7.
目的评价靶向药物与吉西他滨联合用药治疗晚期胰腺癌患者的临床效果和安全性。方法检索中国期刊全文数据库、PubMed、Cochrane图书馆和EMBASE数据库,所选的文献为Ⅲ期随机对照临床试验,关于靶向药物联合吉西他滨的化疗与吉西他滨单用的化疗做有效性和安全性的对比。提取纳入文献的总生存期、无进展生存期、客观缓解率、临床获益率和毒性反应率等资料。对入选研究做Meta分析,并且根据不同的靶向作用机制进行亚组分析查看研究的异质性。文章通过漏斗图和Egger检测法评价偏倚性。结果研究纳入了13篇文献,共6 664例受试者。在Meta分析中,两组总生存期(HR=0.984,95%CI=0.930~1.041,P=0.567)、无进展生存期(HR=0.955,95%CI=0.898~1.015,P=0.137)和客观缓解率(OR=1.188,95%CI=0.978~1.442,P=0.082)差异未见有统计学意义。联合化疗组提高临床获益率(OR=1.249,95%CI=1.039~1.501,P=0.018)。联合化疗组增加了胰腺癌患者3~4级嗜中性白细胞减少症、腹泻和皮疹的不良反应。结论晚期胰腺癌患者接受靶向药物和吉西他滨联合化疗与吉西他滨单用相比,不能提高患者的总生存期和无进展生存期,需要进一步研究靶向药物对晚期胰腺癌的作用。  相似文献   

8.
目的 探讨血小板与淋巴细胞比值(PLR)对非小细胞肺癌(NSCLC)患者预后的评估作用。方法 检索各中英文数据库建库至2017年10月公开发表的关于PLR与非小细胞肺癌预后关系研究的中英文文献,根据纳入与排除标准对文献进行筛选、资料提取和质量评价,筛选后的文献数据用ReviewManager5.3软件进行统计分析,将风险比(HR)与95%可信区间(95%CI)进行合并,并进行各研究间的异质性检验,根据异质性的大小决定采用固定效应模型(P>0.10,I2<50%)或随机效应模型(P<0.10,I2≥50%)进行分析。采用漏斗图进行发表偏倚分析。结果 纳入12篇符合标准的文献,共计3 720例NSCLC患者。PLR与术后总生存率(OS)的关系采用随机模型进行分析(I2=60%,P<0.01),Meta分析结果显示,高PLR组的OS明显低于低PLR组,风险比(HR=1.81),95%可信区间(95%CI:1.47~2.24,P<0.001)。进行亚组分析结果显示,在种族、治疗方法、样本量和PLR截断值等方面,高PLR组的OS明显低于低PLR组(P值均<0.05)。PLR与无病生存率/无进展生存时间(DFS/PFS)的关系采用固定效应模型进行分析(I2=21%,P=0.27),Meta分析结果显示,高PLR组的DFS/PFS明显低于低PLR组(HR=1.42,95%CI:1.22~1.65,P<0.001)。结论PLR升高的NSCLC患者预后较差,PLR可作为评估NSCLC患者预后的指标。  相似文献   

9.
目的综合评价标准化疗方案联合胸腺肽α1(thymosinα1,Tα1)对肿瘤化疗患者疗效及生存预后的影响。方法计算机检索Cochrane Library、Pubmed、Embase、Web of Science、CNKI、CBM、VIP及WANFANG数据库,纳入标准化疗方案联合Tα1用于肿瘤治疗的随机对照试验。根据Cochrane Handbook 5.1.0的质量评价标准,使用Rev Man 5.3对有效率、1年生存率、总生存期(OS)的危险比(HR)和无进展生存期(PFS)危险比进行Meta分析。结果共纳入7项RCT,517例患者,Meta分析结果显示标准化疗方案联合Tα1较单用化疗方案治疗在有效率(RR=1.29,95%CI:1.29~1.64)、1年生存率(RR=1.40,95%CI:1.10~1.79)、OS(HR=0.73,95%CI:0.62~0.87)和PFS(HR=0.83,95%CI:0.73~0.95)方面的差异均有统计学意义(P0.05)。结论在标准化疗方案的基础上联合应用Tα1治疗能提高肿瘤患者的治疗有效率、1年生存率,改善患者的生存质量,延长OS和PFS。  相似文献   

10.
目的探讨胰十二指肠局部切除术后晚期直肠癌患者放化疗预后与MRI指标的相关性。方法使用TexRAD,采用T2加权对化疗前和化疗6周后MRI的过滤直方图技术进行纹理分析(TA)。在轴向图像上手动描绘包含肿瘤最大横截面积的感兴趣区域,并且过滤步骤在不同解剖尺度(精细,中等和粗糙)下提取特征,统计特征(平均强度,标准偏差,熵,偏度,峰度和正像素平均值)。Cox多元回归分析确定了包括组织学,放射学和组织学独立预测的总体生存期(OS),无病生存期(DFS)和无复发生存期(RFS)的单变量特征。结果 MPP(纹理细腻,风险比6.9,95%CI:2.43-19.55,P0.001),平均(中等纹理,HR 5.6,95%CI:1.4-21.7,P=0.007)和室壁静脉入侵(HR 2.96,95%CI:1.04-8.37,P=0.041)独立预测OS,平均值(中等纹理,HR 4.53,95%CI:1.58-12.94,P=0.003)、MPP(纹理细腻,HR 3.36,95%CI:1.36-8.31,P=0.008)和预期的圆周切除边缘(HR 3.1,95%CI:1.01-9.46,P=0.046)预测DFS。对于OS,MRI上的EMVI(HR 4.23,95%CI:1.41-12.69,P=0.01)以及MRI上的DFS峰度(中等纹理,HR3.97,95%CI:1.44-10.94,P=0.007)和CRM累及(HR 3.36,95%CI:1.21-9.32,P=0.02)是独立的治疗后因素。只有TA独立预测治疗前或治疗后分析的RFS。结论基于MR的直肠癌TA可在手术前预测结果,有助选择适合患者的个体化治疗。  相似文献   

11.
The number of older adults worldwide is increasing as societies gain success in improving the health and lifespan of their citizens. As a result, increasing numbers of older adults are presenting to the medical community with advanced kidney failure. Historically, dialysis treatments were withheld from older adults particularly those with severe co-existing illnesses. This has changed in most parts of the world, and there is now an increasing emphasis on shared decision-making to determine whether dialysis is appropriate and to determine which modality meets the needs, expectations, and desire of patients. Evidence examining the difference in risk for death of older adults treated with hemodialysis (HD) or peritoneal dialysis (PD), and the probability of those treated with PD to transfer to HD among older compared to younger adults, is largely derived from prospective cohort studies or analyses of data from national registries. In such studies, it is difficult to distinguish whether differences in outcomes reflect the effect of dialysis modality or differences in health status of different groups of patients. Longevity and technique survival are important, albeit not the only or most important consideration in such decision-making. Given the risk for bias in observational studies and the profound effect of dialysis modality on patients'' lifestyle, the selection of dialysis modality should remain a decision made by the patient, caregivers, and his/her physician after thorough education and review of the available data.  相似文献   

12.
13.
儿童T系急性淋巴细胞白血病的临床研究   总被引:1,自引:0,他引:1  
目的 研究T系急性淋巴细胞白血病(ALL)患儿的临床与预后特征.方法 对1999年1月至2005年4月采用ALL-XH-99方案治疗的305例ALL患儿进行细胞形态学、免疫学、细胞遗传学和分子遗传学分型,并按型分层治疗.结果 在305例ALL患儿中T系ALL患儿43例,其中男34例(79.1%),平均年龄7.8(2.2~16.4)岁,大于10岁的患儿29例(67.4%),中危和高危组患儿分别为11例和32例,WBC≥50×109/L 27例(62.8%),骨髓形态学分型L2 32例,22例患儿出现纵隔增宽.与B系ALL患儿比较,T系ALL患儿在骨髓形态学分型L2比例、大于10岁患儿的比例和WBC≥50×109/L的比例差异均有统计学意义(P<0.05).在诱导缓解治疗中,T系ALL患儿泼尼松窗口试验反应好和第19天骨髓未达缓解的比例分别为62.9%和57.9%,与B系ALL患儿比较,差异均有统计学意义(P值均<0.01).有14例T系ALL患儿复发,完全缓解至复发时间为(1.2±1.5)年.T系ALL患儿的8年无事件生存(EFS)率、无复发生存(RFS)率和总生存(OS)率分别为(40.2±10.1)%、(51.4±11.6)%和(49.8±9.9)%,而B系ALL患儿的8年EFS率、RFS率和OS率分别为(72.1±3.0)%、(83.2±2.7)%和(76.6±2.9)%(P值均<0.01).结论 T系ALL患儿在年龄、白细胞计数和骨髓形态学分型上和B系ALL患儿存在差异,早期治疗反应以及远期疗效较B系ALL患儿差.  相似文献   

14.
目的研究急性髓细胞白血病(AML)患儿miR-126表达水平与预后的相关性。方法选取2014年5月至2016年12月本院收治的AML患儿58例为研究对象,纳入研究组(高危、中危、低危分别16、20、22例),均接受AML标准治疗,同时以本院同期入院的30例非恶性病儿童作为对照组,采用TagMan RT-PCR法检测2组骨髓标本中miR-126表达量,依据出院时miR-126表达量相对水平将AML患儿分为高表达组、低表达组各29例,比较2组miR-126表达量、中位生存时间、无事件生存时间、中位生存率,并根据1年内随访结果将其分为完全缓解组、难治复发组、死亡组,对比3组miR-126表达量,同时分析AML患儿miR-126表达水平与预后的关系。结果研究组miR-126表达量明显高于对照组(P<0.05),且研究组中miR-126表达量依次为高危患儿>中危患儿>低危患儿(P<0.05);miR-126高表达组miR-126表达量(1.52±0.27)高于低表达组,而其中位生存时间(6.21个月)、无事件生存时间(5.34个月)短于低表达组(8.24个月、7.12个月),中位生存率96.55%低于低表达组(P<0.05);完全缓解组出院时、末次随访时miR-126明显低于难治复发组、死亡组,难治复发组、死亡组miR-126表达水平差异也有统计学意义(P<0.05);相关性分析结果显示AML患儿miR-126表达水平与中位生存时间、无事件生存时间、中位生存率呈负相关(P<0.05)。结论AML患儿中miR-126呈高表达状态,且miR-126表达水平与患儿预后关系密切,因而临床可结合miR-126基因检测以提高初治AML患儿的预测准确性。  相似文献   

15.
OBJECTIVES: Selective delta receptor agonists have been shown to stabilize membrane physiologic processes, reduce metabolic rates, and provide protection against ischemic insults through K(ATP) channel opening in a variety of organ beds. However, their potential for affecting outcomes in states of generalized ischemia has not been explored. The authors examined the effect of the nonselective delta receptor agonist, DADLE (D-Ala2-Leu5-enkephalin), on hemodynamic stability and duration of survival in an animal model of severe hemorrhagic shock. METHODS: Conscious Sprague Dawley rats with indwelling catheters were hemorrhaged at a rate of 3.25 mL/100 grams over 20 minutes after half of the group received 1% DADLE (1 mg/kg IV). Following the hemorrhage, all rats were continuously monitored for heart rate (HR), mean arterial pressure (MAP), and life signs for up to three hours (death defined as apnea, systolic blood pressure < 30 mm Hg without pulsations, and electroencephalographic silence). Survival rates and hemodynamic trends were compared between the control and DADLE-treated groups. RESULTS: In the 14 rats studied (8 DADLE; 6 controls), initial hemorrhage resulted in similar hemodynamic shock (average MAP fall: 118 to 59 vs 119 to 55 mm Hg). Analysis of survival at 3.5 hours revealed statistically significant differences between the control and DADLE groups. While 50% of the DADLE group survived past the three hours, no control animals were still alive at the end of the experimental period. The MAP trended downward and the HR increased for the control group, but all hemodynamic parameters stabilized in the rats treated with DADLE. CONCLUSIONS: Most current strategies for treating shock focus on the supply side of resuscitation. The coordinated various actions of DADLE have the potential to work in concert in the intact organism to improve overall survival during severe hemorrhagic shock. In an animal model of severe hemorrhagic shock, there was improvement in hemodynamic stability and a prolonged survival with DADLE treatment. Physiologic manipulation with DADLE appears to be a way to improve survival during shock with possible clinical implications.  相似文献   

16.
17.
Objectives: We studied the effect of body mass index (BMI) at peritoneal dialysis (PD) initiation on patient and technique survival and on peritonitis during follow-up.♦ Methods: We followed 328 incident patients on PD (176 with diabetes; 242 men; mean age: 52.6 ± 12.6 years; mean BMI: 21.9 ± 3.8 kg/m2) for 20.0 ± 14.3 months. Patients were categorized into four BMI groups: obese, ≥25 kg/m2; overweight, 23 - 24.9 kg/m2; normal, 18.5 - 22.9 kg/m2 (reference category); and underweight, <18.5 kg/m2. The outcomes of interest were compared between the groups.♦ Results: Of the 328 patients, 47 (14.3%) were underweight, 171 (52.1%) were normal weight, 53 (16.2%) were overweight, and 57 (17.4%) were obese at commencement of PD therapy. The crude hazard ratio (HR) for mortality (p = 0.004) and the HR adjusted for age, subjective global assessment, comorbidities, albumin, diabetes, and residual glomerular filtration rate (p = 0.02) were both significantly greater in the underweight group than in the normal-weight group. In comparison with the reference category, the HR for mortality was significantly greater for underweight PD patients with diabetes [2.7; 95% confidence interval (CI): 1.5 to 5.0; p = 0.002], but similar for all BMI categories of nondiabetic PD patients.Median patient survival was statistically inferior in underweight patients than in patients having a normal BMI. Median patient survival in underweight, normal, overweight, and obese patients was, respectively, 26 patient-months (95% CI: 20.9 to 31.0 patient-months), 50 patient-months (95% CI: 33.6 to 66.4 patient-months), 57.7 patient-months (95% CI: 33.2 to 82.2 patient-months), and 49 patient-months (95% CI: 18.4 to 79.6 patient-months; p = 0.015). Death-censored technique survival was statistically similar in all BMI categories. In comparison with the reference category, the odds ratio for peritonitis occurrence was 1.8 (95% CI: 0.9 to 3.4; p = 0.086) for underweight patients; 1.7 (95% CI: 0.9 to 3.2; p = 0.091) for overweight patients; and 3.4 (95% CI: 1.8 to 6.4; p < 0.001) for obese patients.♦ Conclusions: In our PD patients, mean BMI was within the normal range. The HR for mortality was significantly greater for underweight diabetic PD patients than for patients in the reference category. Death-censored technique survival was similar in all BMI categories. Obese patients had a greater risk of peritonitis.  相似文献   

18.
19.
目的:探讨中药加味一贯煎在提高晚期肝癌患者生存期及改善生活质量方面的疗效.方法:将复旦大学附属中山医院的原发性肝癌患者100例(男性84例,女性16例)随机分成中药组和对照组,2组均进行常规保肝及对症治疗,中药组加用加味一贯煎,比较2组患者的半年生存率、中位生存期、生活质量评分(Karnofsky)、体力状况美国东部肿瘤协作组(ECOG)评分、中医症候评分.结果:(1)中药组半年生存率为35.80%,中位生存期为114 d;对照组半年生存率为21.21%,中位生存期为71 d,中药组的生存时间显著长于对照组(P=0.041).(2)2组中医症状评分、生活质量评分(Karnofsky标准)、体力状况ECOG评分比较,差异均有统计学意义,中药组在改善症状、提高生活质量、改善体力方面优于对照组.晚期原发性肝癌患者病死危险性与ECOG评分和Child-Pugh分期密切相关.ECOG评分越高,病死的危险越大,即ECOG每增加一个单位,相应病死的危险性增加1.8倍;Child-Pugh评分越高,病死的危险越大,即Child-Pugh每增加一个单位,相应病死的危险性增加1.24倍.结论:加味一贯煎能显著提高晚期原发性肝癌患者半年生存率和中位生存期,改善晚期原发性肝癌患者生活质量和体力状况,降低中医症候评分.  相似文献   

20.

Context

Patients, caregivers, and clinicians require high levels of information regarding prognosis when conditions are incurable.

Objectives

1) To validate the Palliative Prognostic Score (PaP) and 2) to evaluate prognostic capacity of used clinical tools and the diagnosis of delirium, in a population referred to a palliative care consultation service at a Canadian acute care hospital.

Methods

This was a prospective observational cohort study on survival prediction based on the PaP and routinely collected clinical data, including the Palliative Performance Scale (PPS) and the Folstein Mini-Mental State Examination (MMSE). Kaplan-Meier survival curves, log-rank tests for significant differences between survival curves, and the Cox proportional hazards model were used to identify the relationship between the hazard ratio for death and the above variables.

Results

Nine hundred fifty-eight cases underwent final analysis, of which 181 (19%) had a noncancer diagnosis. Median and mean survival were 35 and 131 days, respectively. The three groups, divided based on different ranges of PaP, had significantly different survival curves, with 30-day-survival rates of 78%, 55%, and 11%. Age, PPS, and PaP remained significantly associated with survival, whereas diagnosis group, MMSE, and delirium became insignificant, despite lower hazard of death for cancer vs. noncancer and higher hazard for abnormal vs. normal MMSE and presence vs. absence of delirium.

Conclusion

The PaP was successfully validated in a population with characteristics that extend beyond those of the population in which it was originally developed. This is the largest sample in which the PaP has been validated to date.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号